IRIS
QUINTARELLI, CONCETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.127
NA - Nord America 3.127
EU - Europa 2.396
SA - Sud America 340
Continente sconosciuto - Info sul continente non disponibili 170
AF - Africa 80
OC - Oceania 3
Totale 9.243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.984
SG - Singapore 1.418
RU - Federazione Russa 969
IT - Italia 596
CN - Cina 537
VN - Vietnam 484
HK - Hong Kong 328
BR - Brasile 277
DE - Germania 140
FR - Francia 126
FI - Finlandia 112
UA - Ucraina 105
CA - Canada 90
IE - Irlanda 82
JP - Giappone 75
GB - Regno Unito 71
NL - Olanda 71
BD - Bangladesh 69
IN - India 55
SE - Svezia 30
PL - Polonia 25
MX - Messico 22
ZA - Sudafrica 22
KR - Corea 21
ES - Italia 19
AR - Argentina 18
IQ - Iraq 17
PH - Filippine 17
ID - Indonesia 15
EC - Ecuador 12
TH - Thailandia 11
TR - Turchia 11
LT - Lituania 10
CI - Costa d'Avorio 9
UZ - Uzbekistan 9
AT - Austria 8
CL - Cile 8
CO - Colombia 8
PK - Pakistan 8
SC - Seychelles 8
MA - Marocco 7
AE - Emirati Arabi Uniti 6
EG - Egitto 6
ET - Etiopia 6
JM - Giamaica 6
LV - Lettonia 6
VE - Venezuela 6
SA - Arabia Saudita 5
TW - Taiwan 5
BE - Belgio 4
BO - Bolivia 4
DZ - Algeria 4
GT - Guatemala 4
HR - Croazia 4
PY - Paraguay 4
BW - Botswana 3
CH - Svizzera 3
CR - Costa Rica 3
GE - Georgia 3
HU - Ungheria 3
IL - Israele 3
IR - Iran 3
JO - Giordania 3
KW - Kuwait 3
KZ - Kazakistan 3
MK - Macedonia 3
MY - Malesia 3
NI - Nicaragua 3
SN - Senegal 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
CW - ???statistics.table.value.countryCode.CW??? 2
EU - Europa 2
LA - Repubblica Popolare Democratica del Laos 2
ML - Mali 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
RO - Romania 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CU - Cuba 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GN - Guinea 1
Totale 9.061
Salva come PNG Salva come JPEG
Città #
Singapore 648
San Jose 479
Hong Kong 319
Ashburn 264
Moscow 222
Chandler 198
Council Bluffs 159
Beijing 147
Ho Chi Minh City 113
Hanoi 105
Santa Clara 103
Millbury 87
Lauterbourg 75
Los Angeles 73
The Dalles 70
Tokyo 65
Hefei 64
Napoli 61
Munich 60
Rome 60
Amsterdam 56
Buffalo 56
Dong Ket 48
Naples 46
Princeton 46
Nanjing 40
New York 39
Milan 37
São Paulo 35
Turku 34
Des Moines 33
Boston 32
Frisco 32
Redondo Beach 32
Jacksonville 30
Brooklyn 26
Dallas 26
Wilmington 26
Lawrence 24
Toronto 24
Orem 23
Frankfurt am Main 22
Helsinki 22
Chennai 21
London 21
Montreal 21
Ottawa 21
Da Nang 19
Dublin 19
Warsaw 19
Haiphong 18
Atlanta 16
Chicago 16
Phoenix 15
San Francisco 15
Seattle 15
Johannesburg 13
Nuremberg 13
Poplar 13
Denver 12
Falkenstein 11
Falls Church 11
Houston 10
Jiaxing 10
Mexico City 10
Rio de Janeiro 10
Seoul 10
Turin 10
Brasília 9
Fairfield 9
Lappeenranta 9
Mumbai 9
Nanchang 9
Shenyang 9
Tianjin 9
Brescia 8
Chongqing 8
Miami 8
Redwood City 8
Biên Hòa 7
Changsha 7
Charlotte 7
Guangzhou 7
Guidonia 7
Raleigh 7
Stockholm 7
Tashkent 7
Ninh Bình 6
Quận Ba 6
Riga 6
Salerno 6
Verona 6
Addis Ababa 5
Ankara 5
Augusta 5
Bologna 5
Florence 5
Hải Dương 5
Kingston 5
Manchester 5
Totale 4.751
Salva come PNG Salva come JPEG
Nome #
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 452
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 223
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 180
Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies 178
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 172
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 165
Advanced-stage Hodgkin Lymphoma: US/Chest Radiography for Detection of Relapse in Patients in First Complete Remission—A Randomized Trial of Routine Surveillance Imaging Procedures 161
Spleen is the dark side of essential Thrombocitemia 160
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 155
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 151
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies 148
Adoptive immunotherapy using prame-specific t cells in medulloblastoma 147
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 144
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene 144
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells 139
SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best 137
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib. 137
CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL 137
Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation 135
Cytotoxic T lymphocytes directed to the Preferentially Expressed Antigen of Melanoma (PRAME) target chronic myeloid leukemia. 129
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 127
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 127
PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism 126
Molecular monitoring in chronic myeloid leukemia (CML) 118
Preferentially expressed antigen of melanoma (PRAME)-specific cytotoxic T-Lymphocytes (CTLs) and transgenic T cells to target chronic myelogenous leukemia (CML) 117
Decitabine up-regulates the expression of the cancer-associate prame antigen in early chronic phase CML cells. 117
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. 115
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma 114
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia 113
Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing 113
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model 112
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients 109
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 108
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells 106
The biological resources and molecule archives organization: Turn a need into an opportunity for the Smart Specialization Strategy of the Lazio region 106
A small animal in vivo imaging model of expanded vs. unexpanded UCB stem cells reveals differential patterns of engraftment 103
Co-Expression of a Chimeric Antigen Receptor Targeting CD19 (CAR19), Optimized Human IL-15, and iCaspase9 To Enhance the Activity and Safety of Cytotoxic T Lymphocytes 102
Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. 100
Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia. 100
Gene therapy to improve function of T cells for adoptive immunotherapy. 99
Gene transfer of IL-7R alpha (IL-7R alpha) on antigen-specific cytotoxic T cells (CTLs) restores their ability to respond to IL-7 cytokine 99
Generation of Epstein Barr Virus Specific Cytotoxic T Lymphocytes (EBV-CTLs) Resistant to the Immunosuppressive Drug Tacrolimus (FK506) 99
CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL 99
Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring 99
Allogeneic CAR T cells: A new player in the field and the peculiar opportunities of the hospital exemption path 98
Transgenic expression of inducible caspase9 suicide gene for in vivo elimination of antigen specific cytotoxic T cells (CTLs) engineered to produce cytokines. 94
Overcoming challenges in CAR T-cell product CGMP release 94
Induction of PRAME-specific immunity by overlapping pentadecapeptides in patients with hematologic malignancies 93
Ethics-aware data governance (Vision Paper) 90
Generation of EBV specific cytotoxic T lymphocytes (EBV-CTLs) resistant to the immunosuppressive drug FK506 89
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma 88
Hepatitis B virus reactivation after fludarabine-based regiments for indolent non-Hodgkin’s lymphomas: high prevalence of acquired viral genomic mutations. 88
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. 88
Polyclonal PRAME-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia 87
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. 86
Engineering CD19-Redirected T Lymphocytes to Enhance Their Safety and Efficacy 85
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells 84
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19 84
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring 84
Stimuli-responsive nanoparticle-assisted immunotherapy: A new weapon against solid tumours 84
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks 83
Transgenic expression of IL15 selectively expands antigen specific cytotoxic T cells (CTLs) enhancing their anti-tumor effect in vivo. 82
Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9 81
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma 78
Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse 75
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). 73
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7 71
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia. 70
Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients 69
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy 67
The immune system of children: the key to understanding SARS-CoV-2 susceptibility? 67
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia 63
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study 60
Generation and expansion of PRAME-specific cytotoxic T-lymphocytes for adoptive T-cell therapy of hematological malignancies. 58
NK Cell-Based Immunotherapy for Hematological Malignancies 58
Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia 57
Preservation of antigen-specific functions of αβ T cells and B cells removed from hematopoietic stem cell transplants suggests their use as an alternative cell source for advanced manipulation and adoptive immunotherapy 57
Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells 52
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. 52
MicroRNAs in neuroblastoma: Biomarkers with therapeutic potential 52
Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis 49
The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe 49
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis 46
A biodegradable hydrogel based on carboxymethyl cellulose/silver nanoparticles for wound closures 18
GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango? 14
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? 12
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial 12
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting 11
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape 10
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. 10
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma 9
SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity 9
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches 9
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma 9
The immune response as a double-edged sword: The lesson learnt during the COVID-19 pandemic 9
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles 9
Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters 8
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply 8
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia 8
Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling 8
Totale 9.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.270
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.270
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022461 0 2 5 9 5 17 7 17 82 23 130 164
2022/2023511 73 32 20 10 65 57 8 67 92 47 24 16
2023/2024309 17 51 46 23 15 25 6 23 10 9 64 20
2024/20252.223 101 155 9 26 59 100 224 147 128 222 751 301
2025/20264.438 482 303 435 442 718 162 479 248 434 359 244 132
2026/2027433 171 262 0 0 0 0 0 0 0 0 0 0
Totale 9.243